Can a mildly elevated ALT accompany metabolic fatty liver and hepatic insulin resistance?

A mild alanine aminotransferase (ALT) elevation is compatible with metabolic dysfunction–associated steatotic liver disease (MASLD) and hepatic insulin resistance, including when routine liver tests or conventional imaging appear normal. It is an accompanying clue, not a diagnosis.

Clinical and metabolic evidence

• ALT alone neither confirms nor excludes MASLD. Liver enzymes are within reference limits in an estimated 50–79% of people with NAFLD/MASLD, so normal ALT is not reassuring enough to rule it out.
• In 1,309 nondiabetic adults, ALT correlated modestly with a hepatic insulin-resistance index derived from fasting insulin and endogenous glucose production (men r=0.25; women r=0.18), persisting after metabolic adjustment.
• In Pima adults, higher ALT was associated with poorer insulin-mediated suppression of hepatic glucose production, and baseline ALT predicted later deterioration in hepatic insulin sensitivity. Importantly, these relationships were seen even across conventionally normal ALT values.

Imaging and detection

• A normal conventional ultrasound does not exclude low-grade steatosis. Sensitivity for mild disease is estimated at roughly 70%, and ultrasound may not detect steatosis below approximately 20% liver fat.
• MR proton spectroscopy has high discrimination for mild steatosis in biopsy-comparison research and can identify liver fat missed by conventional ultrasound.

Interpretation and clinical implications

• ALT is an indirect, nonspecific marker of hepatocellular injury; it does not directly measure liver fat, hepatic glucose production, or insulin responsiveness. A mild rise should not automatically be attributed to MASLD, as alcohol, viral hepatitis, medications, muscle injury, and other causes remain clinically relevant.
• Fibrosis risk requires separate assessment—e.g., FIB-4 and, when indicated, elastography—rather than reliance on ALT or ultrasound alone.

Bottom line

• Mild ALT elevation can accompany MASLD and hepatic insulin resistance despite normal routine testing or ultrasound, but it neither establishes nor rules out either condition.